Nascent Biotech Stock Price, News & Analysis

Nascent Biotech (OTCQB:NBIO) has completed the third cohort in its Phase I clinical trial for Brain Cancer, advancing toward the fourth and potentially final cohort. Although the third cohort took longer than expected, the data is deemed useful for future directions. Patient enrollment is ongoing, and the company plans to conduct pharmacokinetic studies to assess the need for a fifth cohort. Pritumumab (PTB) is a targeted immunotherapy designed to selectively target cancer cells without harming healthy cells, marking a significant advancement in cancer treatment.

Nascent Biotech (OTCQB:NBIO) announced that its CEO, Sean Carrick, was interviewed by Proactive Investors, discussing the company's progress with its Phase I Clinical Trial for Pritumumab (PTB), a monoclonal antibody targeting cancers originating in epithelial cells. Carrick emphasized the company's ongoing development of PTB, with plans to advance to Phase II trials, which could significantly benefit shareholders. The interview highlighted milestones achieved in monoclonal antibody development and a vaccine platform utilizing r-BCG to combat viral infections.

Nascent Biotech has announced a partnership with BioTools, focusing on the monoclonal antibody Pritumumab (PTB), aimed at treating brain cancer. This collaboration leverages BioTools' advanced ROA laser-based technology to enhance the characterization of PTB's higher-order molecular structure, potentially improving its effectiveness and applications. PTB, currently in Phase I clinical trials, is expected to benefit from BioTools' expertise in biologic characterization, aiding in the optimization of its pharmaceutical properties.

Nascent Biotech has partnered with Sharp HealthCare to initiate a Phase I clinical trial for Pritumumab (PTB), an innovative immunotherapy targeting glioblastoma, a severe brain cancer. This trial is designed to explore Pritumumab's efficacy against brain tumors and has potential implications for treating other epithelial cancers. Sharp HealthCare's robust cancer program is a key asset in this collaboration. The trial reflects a commitment to addressing significant unmet medical needs in oncology, with an estimated 23,000 new GBM cases annually in the U.S.

Nascent Biotech has received a milestone payment of USD $750,000 from BioRay Pharmaceutical as part of their licensing agreement for the monoclonal antibody Pritumumab. This payment marks the second of four payments totaling USD $5 million, following an initial USD $1 million received in April 2021. The next payment of USD $2.5 million is contingent upon FDA approval for a Phase 2 clinical trial, with the final USD $750,000 due upon trial commencement. Pritumumab is currently in Phase 1 trials targeting brain cancer.

Nascent Biotech (OTCQB:NBIO) has completed dosing for the second cohort in its Phase I trial evaluating Pritumumab (PTB) as a treatment for brain cancer. This achievement allows the company to advance to its third cohort, anticipated to commence shortly. PTB is a targeted immunotherapy designed to specifically attack cancer cells without harming healthy cells. Positive data trends have been reported, paving the way for a future petition for Phase 2 testing. The company continues to push forward in its mission to develop innovative cancer treatments.

Nascent Biotech (OTCQB:NBIO) and its partner, Manhattan BioSolutions, have reported promising preclinical results for a COVID-19 vaccine candidate based on a modified BCG vaccine originally developed for tuberculosis. The vaccine, termed BCG-S, demonstrated significant cellular immune responses in mice, indicating potential effectiveness. Moving forward, additional experiments will investigate the protective efficacy of this vaccine. Both companies express optimism about their collaboration and aim to advance innovative therapies to improve patient outcomes.

Nascent Biotech (OTCQB: NBIO) announced the release of an analyst report by Marble Arch Research, which rates the stock a Speculative Buy with a target price of $0.39 to $1.99. The report emphasizes the potential for significant market value growth as the company's lead drug, Pritumumab (PTB), progresses through clinical trials. Currently, PTB is in an FDA-approved Phase I trial targeting primary and metastatic brain cancer. The CEO expressed optimism for future developments in treating cancers and viral infections.

Nascent Biotech (OTCQB:NBIO) has commenced enrollment for the second cohort in its Phase I trial for treating Brain Cancer with its lead candidate, Pritumumab (PTB). This trial milestone allows for tripling dosage levels over the first cohort, targeting the highest dose without toxicity. PTB, a natural human antibody, targets Cell surface Vimentin to specifically attack cancer cells, sparing healthy ones. The ongoing Phase I trial signifies advancements in targeted immunotherapy, with development for COVID-19 also underway.